专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09931360B2 Isolated liver stem cells 有权
公开(公告)号：US09931360B2
公开(公告)日：2018-04-03
申请号：US15686729
申请日：2017-08-25
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： C12N5/074 , C12N5/071 , C12N5/10 , A61K35/28 , G01N33/50 , A61K35/407
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.

2. 发明申请

US20150306147A1 ISOLATED LIVER STEM CELLS 有权
标题翻译：分离肝脏干细胞
公开(公告)号：US20150306147A1
公开(公告)日：2015-10-29
申请号：US14795195
申请日：2015-07-09
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： A61K35/28
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.
摘要翻译：通过治疗个体，例如患有肝的先天性的患者，代谢缺陷，与人类祖细胞或干细胞，细胞群体或其后代相关的方法，可以公开治疗基于肝的先天性代谢缺陷的方法。用于治疗的细胞具有以下特征。它们对波形蛋白，α-平滑肌肌动蛋白（ASMA）和至少一种间质标志物如CD90，CD29，CD73和CD44是阳性的。它们对于至少一种肝细胞标志物如白蛋白，甲胎蛋白，α-1抗胰蛋白酶，HNF-4和MRP2转运蛋白是阳性的。它们表达至少一种肝细胞样的性质或功能，如G6P，CYP1B1，CYP3A4，TDO，TAT，GS，GGT，CK8和EAAT2。它们对于至少一种标记如细胞角蛋白-19，CD45，CD34，CD49f，CD133，HLA-DR和CD117是阴性的。它们具有间充质形态。它们源于人类成年肝细胞。

3. 发明申请

US20140286917A1 ISOLATED LIVER STEM CELLS 有权
标题翻译：分离肝脏干细胞
公开(公告)号：US20140286917A1
公开(公告)日：2014-09-25
申请号：US14294886
申请日：2014-06-03
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： C12N5/071 , A61K35/407
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed.
摘要翻译：公开了分离的肝脏祖细胞干细胞和分离的肝脏祖细胞干细胞的细胞群。祖细胞源于成年肝脏，特别是成人肝脏。分离的祖细胞干细胞在医学，肝病学，肝脏代谢移植，先天性肝脏代谢异常，传染病和肝功能衰竭方面都有应用。描述了分离这些细胞及其培养物的方法。分离细胞的特征在分化前后。公开了其用于移植和用作人类疾病，毒理学和药理学的动物模型。

4. 发明授权

US08778607B2 Method of in vitro toxicity testing using isolated liver stem cells 有权
标题翻译：使用分离的肝干细胞的体外毒性试验方法
公开(公告)号：US08778607B2
公开(公告)日：2014-07-15
申请号：US14152673
申请日：2014-01-10
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： C12Q1/00 , C12N5/074
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： A method of conducting in vitro toxicity testing is disclosed which includes the steps of exposing to a test agent a population of human liver progenitor or stem cells originated from human adult liver. The cells have the characteristics that the isolated human progenitor or stem cells express at least the mesenchymal markers vimentin and α-smooth muscle actin (ASMA), the hepatocyte marker albumin (ALB), are negative for cytokeratin-19 (CK-19), and have mesenchymal-like morphology. One or more effects, if any, of the test agent on the population of human liver progenitor or stem cells are observed. Also disclosed are methods of conducting in vitro drug metabolism studies by exposing to a test agent a population of the human liver progenitor or stem cells and methods of testing infected human liver progenitor or stem cells for effects of a test agent.
摘要翻译：公开了进行体外毒性试验的方法，其包括将来自人成人肝脏的人肝脏祖细胞或干细胞群体暴露于测试试剂的步骤。细胞具有分离的人类祖细胞或干细胞至少表达间质标志物波形蛋白和α-平滑肌肌动蛋白（ASMA），肝细胞标志物白蛋白（ALB）对于细胞角蛋白-19（CK-19）是阴性的特征，并具有间充样形态。观察到对人类肝脏祖细胞或干细胞群体的一种或多种作用（如果有的话）。还公开了通过将测试试剂暴露于人肝脏祖细胞或干细胞的群体进行体外药物代谢研究的方法以及测试感染的人类肝脏祖细胞或干细胞以测试试剂的作用的方法。

5. 发明申请

US20170354687A1 ISOLATED LIVER STEM CELLS 有权
公开(公告)号：US20170354687A1
公开(公告)日：2017-12-14
申请号：US15686729
申请日：2017-08-25
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： A61K35/28 , C12N5/071 , A61K35/407 , G01N33/50
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.

6. 发明授权

US09775863B2 Isolated liver stem cells 有权
公开(公告)号：US09775863B2
公开(公告)日：2017-10-03
申请号：US14795195
申请日：2015-07-09
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： C12N5/071 , C12N5/10 , A61K35/28 , G01N33/50 , A61K35/407
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.

7. 发明授权

US09107910B2 Isolated liver stem cells 有权
标题翻译：分离肝干细胞
公开(公告)号：US09107910B2
公开(公告)日：2015-08-18
申请号：US14294886
申请日：2014-06-03
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： C12N5/074 , C12N5/071 , A61K48/00 , C12N15/00 , A61K35/407 , G01N33/50
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed.
摘要翻译：公开了分离的肝脏祖细胞干细胞和分离的肝脏祖细胞干细胞的细胞群。祖细胞源于成年肝脏，特别是成人肝脏。分离的祖细胞干细胞在医学，肝病学，肝脏代谢移植，先天性肝脏代谢异常，传染病和肝功能衰竭方面都有应用。描述了分离这些细胞及其培养物的方法。分离细胞的特征在分化前后。公开了其用于移植和用作人类疾病，毒理学和药理学的动物模型。

8. 发明申请

US20140127676A1 ISOLATED LIVER STEM CELLS 有权
标题翻译：分离肝脏干细胞
公开(公告)号：US20140127676A1
公开(公告)日：2014-05-08
申请号：US14152673
申请日：2014-01-10
申请人： Universite Catholique de Louvain
发明人： Etienne Sokal , Mustapha Najimi
IPC分类号： G01N33/50
CPC分类号： A61K35/28 , A61K35/407 , C12N5/0672 , G01N33/5067
摘要： A method of conducting in vitro toxicity testing is disclosed which includes the steps of exposing to a test agent a population of human liver progenitor or stem cells originated from human adult liver. The cells have the characteristics that the isolated human progenitor or stem cells express at least the mesenchymal markers vimentin and α-smooth muscle actin (ASMA), the hepatocyte marker albumin (ALB), are negative for cytokeratin-19 (CK-19), and have mesenchymal-like morphology. One or more effects, if any, of the test agent on the population of human liver progenitor or stem cells are observed. Also disclosed are methods of conducting in vitro drug metabolism studies by exposing to a test agent a population of the human liver progenitor or stem cells and methods of testing infected human liver progenitor or stem cells for effects of a test agent.
摘要翻译：公开了进行体外毒性试验的方法，其包括将来自人成人肝脏的人肝脏祖细胞或干细胞群体暴露于测试试剂的步骤。细胞具有分离的人类祖细胞或干细胞至少表达间质标志物波形蛋白和α-平滑肌肌动蛋白（ASMA），肝细胞标志物白蛋白（ALB）对于细胞角蛋白-19（CK-19）是阴性的特征，并具有间充样形态。观察到对人类肝脏祖细胞或干细胞群体的一种或多种作用（如果有的话）。还公开了通过将测试试剂暴露于人肝脏祖细胞或干细胞的群体进行体外药物代谢研究的方法以及测试感染的人类肝脏祖细胞或干细胞以测试试剂作用的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式